Aquestive Therapeutics (AQST) News Today $3.02 -0.19 (-5.92%) Closing price 04:00 PM EasternExtended Trading$3.02 0.00 (-0.17%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period EntryPoint Capital LLC Acquires 112,210 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)EntryPoint Capital LLC increased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 475.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,797 shares of the company's stocMarch 27 at 4:58 AM | marketbeat.comAquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyMarch 25 at 9:02 AM | seekingalpha.comAquestive Therapeutics: Not For Me, But AttractiveMarch 24, 2025 | seekingalpha.comAnalysts Offer Predictions for AQST FY2026 EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for Aquestive Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.56)March 12, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for AQST Q1 Earnings?Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju expectsMarch 12, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comAquestive Therapeutics (NASDAQ:AQST) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Monday.March 10, 2025 | marketbeat.comEarnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their ForecastsMarch 8, 2025 | uk.finance.yahoo.comAquestive Therapeutics (NASDAQ:AQST) Price Target Cut to $8.00 by Analysts at Lake Street CapitalLake Street Capital reduced their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Friday.March 8, 2025 | marketbeat.comRaymond James Keeps Their Buy Rating on Aquestive Therapeutics (AQST)March 7, 2025 | markets.businessinsider.comAquestive Therapeutics price target lowered to $7 from $8 at Raymond JamesMarch 7, 2025 | markets.businessinsider.comAquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...March 7, 2025 | finance.yahoo.comAlliance Global Partners Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)March 7, 2025 | markets.businessinsider.comAquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global PartnersMarch 7, 2025 | markets.businessinsider.comAquestive Therapeutics Reports 2024 Financial Results and Strategic ProgressMarch 6, 2025 | tipranks.comAquestive Therapeutics sees FY25 revenue $47M-$56M , consensus $52.97MMarch 6, 2025 | markets.businessinsider.comAquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPSAquestive Therapeutics (NASDAQ:AQST - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05).March 6, 2025 | marketbeat.comAquestive Therapeutics misses Q4 estimates, shares fallMarch 6, 2025 | uk.investing.comAquestive Therapeutics misses Q4 estimates, shares fallMarch 6, 2025 | uk.investing.comAquestive Therapeutics reports Q4 EPS (19c), consensus (13c)March 6, 2025 | markets.businessinsider.comAquestive Therapeutics reports Q4 EPS (19c), consensus (13c)March 6, 2025 | markets.businessinsider.comAquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver LiningsMarch 6, 2025 | msn.comAquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver LiningsMarch 6, 2025 | msn.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from BrokeragesAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received a consensus recommendation of "Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommMarch 6, 2025 | marketbeat.comAquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5, 2025 | globenewswire.comAquestive Therapeutics Q4 2024 Earnings PreviewMarch 4, 2025 | msn.comAquestive Therapeutics to Participate in Two Upcoming Conferences in MarchFebruary 26, 2025 | markets.businessinsider.comAquestive Therapeutics (AQST) to Release Earnings on WednesdayAquestive Therapeutics (NASDAQ:AQST) will be releasing earnings after the market closes on Wednesday, March 5, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637658)February 26, 2025 | marketbeat.comShort Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Decreases By 5.9%Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 11,090,000 shares, a decline of 5.9% from the January 15th total of 11,790,000 shares. Based on an average daily trading volume, of 1,470,000 shares, the short-interest ratio is presently 7.5 days.February 18, 2025 | marketbeat.comAquestive Therapeutics to present new findings at AAAAI meetingFebruary 12, 2025 | markets.businessinsider.comHarvey Capital Management Inc. Has $952,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Harvey Capital Management Inc. grew its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 1,419.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 267,390 shares of the company'February 12, 2025 | marketbeat.comAquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual MeetingFebruary 12, 2025 | globenewswire.comBrokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a stronFebruary 12, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received a consensus rating of "Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the companFebruary 9, 2025 | marketbeat.comAquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare ConferenceFebruary 4, 2025 | markets.businessinsider.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Significant Growth in Short InterestAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 10,480,000 shares, an increase of 8.6% from the December 31st total of 9,650,000 shares. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is currently 6.8 days.February 2, 2025 | marketbeat.comInstitutional investors own a significant stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST)January 27, 2025 | finance.yahoo.comCantor Fitzgerald Comments on AQST FY2025 EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earningsJanuary 22, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in DecemberAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 10,480,000 shares, an increase of 8.6% from the December 15th total of 9,650,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio is presently 6.8 days.January 19, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $11.00 Consensus Target Price from AnalystsShares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to tJanuary 18, 2025 | marketbeat.comPromising Pipeline and Solid Financials: Analyst’s Buy Rating on Aquestive TherapeuticsJanuary 15, 2025 | markets.businessinsider.comAquestive Therapeutics: Promising Growth Trajectory with Strategic Initiatives and Strong Market PotentialJanuary 14, 2025 | markets.businessinsider.comAquestive Therapeutics provides business updateJanuary 13, 2025 | markets.businessinsider.comAquestive Therapeutics: Five Foci For 2025January 6, 2025 | seekingalpha.comState Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)State Street Corp boosted its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 52.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,496,739 shares of the company's stock after purchasing an additDecember 28, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial CorpStifel Financial Corp cut its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 75.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,944 shares of the company's stock after sellinDecember 28, 2024 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of "Buy" from AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has earned a consensus rating of "Buy" from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy ratDecember 21, 2024 | marketbeat.comAquestive Therapeutics Gains Buy Rating Amid Orphan Drug Exclusivity and Promising Product PipelineDecember 20, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday.December 20, 2024 | marketbeat.comAquestive Therapeutics receives FDA ODE for Libervant Buccal FilmDecember 20, 2024 | markets.businessinsider.com Remove Ads Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Media Mentions By Week AQST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼1.380.78▲Average Medical News Sentiment AQST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼43▲AQST Articles Average Week Remove Ads Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EVO News SPRY News ARDX News OCUL News GPCR News CALT News IOVA News SNDX News AUPH News SYRE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AQST Stock Free AQST Stock Alerts